KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study.

Lin Cai, Xiao-Yong Man, Jinyan Wang, Aihua Wei, Ying Chen, Delphine Deherder, Jun Gao, Bengt Hoepken, Weiwei Sun, Tingting Lei, Jianzhong Zhang, BE SHINING Study Group

J Eur Acad Dermatol Venereol 40(6) 1019-1029

PMID41678327
PMCIDPMC13206364
DOI10.1111/jdv.70350
发表日期2026-02-12
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:研究设计图;FIGURE 2:AI 判定为 flow diagram;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 multi panel km。
摘要

摘要

BACKGROUND: Bimekizumab was well tolerated and demonstrated superior efficacy in global psoriasis studies; however, these included few Chinese patients. OBJECTIVES: To evaluate the efficacy and safety of bimekizumab in Chinese patients with moderate to severe plaque psoriasis. METHODS: In BE SHINING, patients were randomized 3:1 to bimekizumab 320 mg every 4 weeks (Q4W) to Week 16 then every 8 weeks (Q8W) to Week 32, or to placebo Q4W to Week 16 then bimekizumab Q4W to Week 32. Primary endpoints included achievement of ≥90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) and Investigator's Global Assessment (IGA) of 0/1 at Week 16. Secondary endpoints included PASI 75/PASI 100 response rates at Week 4/16, respectively. Missing data were imputed as non-response; p values were based on the Cochran-Mantel-Haenszel test. Safety outcomes were assessed in patients who received ≥1 treatment dose (Weeks 0-32). RESULTS: Overall, 133 patients were randomized (bimekizumab Q4W/Q8W: N = 100; placebo/bimekizumab Q4W: N = 33). Bimekizumab-treated patients had significantly higher primary endpoint response rates versus placebo (Week 16; PASI 90: 94.0% vs. 3.0%; IGA 0/1: 92.0% vs. 3.0%; p < 0.001 for both), and significantly higher rates of PASI 75 (Week 4; 74.0% vs. 3.0%; p < 0.001) and PASI 100 (Week 16; 65.0% vs. 0.0%; p < 0.001). Response rates were similar in bimekizumab Q4W/Q8W and placebo/bimekizumab Q4W patients at Week 32. Through Week 32, in patients who received ≥1 bimekizumab dose, rates of treatment-emergent adverse events (TEAEs), serious TEAEs and TEAEs leading to discontinuation were 73.8%, 6.2% and 5.4%. The most common TEAEs were upper respiratory tract infection, hepatic function abnormal and injection site pain; no new safety signals were identified. CONCLUSIONS: Bimekizumab treatment was well tolerated and led to significantly higher clinical response rates versus placebo, including complete skin clearance, in Chinese patients with moderate to severe psoriasis. Findings were consistent with global studies.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Study design. BKZ, bimekizumab; IGA 0/1, Investigator's Global Assessment score of 0 (clear) or 1 (almost‐clear) with ≥2‐category improvement relative to baseline, scored on a 5‐point scale; PASI 90, ≥90% improvement from baseline in Psoriasis Area and Severity Index; PBO, placebo; Q4W, every 4 weeks; Q8W, every 8 weeks.
非 KM Figure
FIGURE 2FIGURE 2 Patient disposition. a One patient in the BKZ 320 mg Q4W/Q8W group discontinued treatment during the initial treatment period but remained in the study and never received any treatment in the maintenance treatment period; therefore, this patient was not counted as entering the maintenance treatment period. BKZ, bimekizumab; PBO, placebo; Q4W, every 4 weeks; Q8W, every 8 weeks; SFU, safety follow‐up.
非 KM Figure
FIGURE 3FIGURE 3 PASI 90 and IGA 0/1 response rates at Week 16 and through Week 32 (NRI). (a) PASI 90; (b) IGA 0/1. Randomized set (all study patients randomized to treatment). p values were used for comparisons based on the Cochran–Mantel–Haenszel test. Patients receiving PBO switched to BKZ Q4W from Week 16. BKZ, bimekizumab; CI, confidence interval; IGA 0/1, Investigator's Global Assessment response of clear (0) or almost clear (1) with ≥2‐category improvement relative to baseline, scored on a 5‐point scale; NRI, non‐responder imputation; PASI 90, ≥90% improvement from baseline in Psoriasis Area and Severity Index; PBO, placebo; Q4W, every 4 weeks; Q8W, every 8 weeks; RD, risk difference.
非 KM Figure
FIGURE 4FIGURE 4 PASI 75 and PASI 100 response rates at Week 4/Week 16 and through Week 32 (NRI). (a) PASI 75; (b) PASI 100. Randomized set (all study patients randomized to treatment). p values were used for comparisons based on the Cochran–Mantel–Haenszel test. Patients receiving PBO switched to BKZ Q4W from Week 16. BKZ, bimekizumab; CI, confidence interval; NRI, non‐responder imputation; PASI 75/100, ≥75%/100% improvement from baseline in Psoriasis Area and Severity Index; PBO, placebo; Q4W, every 4 weeks; Q8W, every 8 weeks; RD, risk difference.
非 KM Figure